Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Hypertension

Drospirenone with 17 beta-estradiol may lead to cardiovascular risk reduction

Researchers from the United States stated, "Drospirenone (DRSP) is a novel progestin with antimineralocorticoid activity that has been developed for hormone therapy in combination with 17 beta-estradiol (E2) in postmenopausal women. In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)."

W.B. White and colleagues evaluated "The effects of 3 mg DRSP/1 mg E2 on clinic and 24-hour ambulatory BP as well as...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications